Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association

Rhea-AI Summary

Eledon Pharmaceuticals (Nasdaq: ELDN) announced that its President and Chief Scientific Officer, Steve Perrin, Ph.D., will present at the 18th Congress of the International Xenotransplantation Association (IXA) in Geneva, Switzerland. The presentation will take place on October 1, 2025, from 10:30 a.m. to 12:00 p.m. CET during a plenary session focused on immunosuppression and anti-CD154 pathway blockade.

News Market Reaction – ELDN

+2.07%

5 alerts

+2.07% Session close to close

$153.30M Market Cap

0.6x Rel. Volume

In the Sep 25 session, ELDN gained 2.07%, reflecting a moderate positive market reaction. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

IRVINE, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D., President and Chief Scientific Officer, will participate in a plenary session at the upcoming 18^th Congress of the International Xenotransplantation Association (IXA) taking place from September 30–October 3, 2025, in Geneva, Switzerland.

Details are as follows:

Plenary Session: Immunosuppression, Immune Monitoring, Anti-CD154* Pathway Blockade: How Far do We Need to Go?
Lecture Title: 201.2 Anti-CD154 Pathway Blockade
Date: Wednesday, October 1, 2025
Time: 10:30 a.m. – 12:00 p.m. CET
*CD154 is also known as CD40L or CD40 Ligand

About Eledon Pharmaceuticals and tegoprubart

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter

Investor Contact:

Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com

Media Contact:

Jenna Urban
CG Life
(212) 253 8881
jurban@cglife.com

Source: Eledon Pharmaceuticals

FAQ

When is Eledon Pharmaceuticals (ELDN) presenting at the IXA Congress 2025?

Eledon will present on Wednesday, October 1, 2025, from 10:30 a.m. to 12:00 p.m. CET in Geneva, Switzerland.

Who will be presenting for Eledon Pharmaceuticals at the IXA Congress 2025?

Steve Perrin, Ph.D., President and Chief Scientific Officer of Eledon Pharmaceuticals, will be presenting.

What topic will Eledon Pharmaceuticals (ELDN) discuss at the IXA Congress 2025?

The presentation will focus on Anti-CD154 Pathway Blockade as part of a plenary session on immunosuppression and immune monitoring.

Where is the 18th Congress of the International Xenotransplantation Association being held?

The congress is being held in Geneva, Switzerland from September 30 to October 3, 2025.